Adrian Kilcoyne - Feb 16, 2024 Form 4 Insider Report for Celularity Inc (CELU)

Role
Chief Medical Officer
Signature
/s/ Kyle Fletcher, Attorney-in-Fact
Stock symbol
CELU
Transactions as of
Feb 16, 2024
Transactions value $
-$22,899
Form type
4
Date filed
2/21/2024, 09:38 PM
Previous filing
Jul 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CELU Class A Common Stock Tax liability -$22.9K -52.8K -4.49% $0.43 1.12M Feb 17, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CELU Stock Option Grant (Right to Buy) Award $0 +205K $0.00 205K Feb 16, 2024 Class A Common Stock 205K $0.43 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Issuer to satisfy the Reporting Person's tax obligations associated with the vesting and settlement of restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan") and does not represent a sale.
F2 Reflects shares underlying RSUs subject to vesting.
F3 The option was granted pursuant to the 2021 Plan. The shares underlying such option will vest in equal quarterly installments during 2024 such that 25% of the option will vest on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, subject to the Reporting Person's continuous service with the Issuer through each such date.